Adaptive Biotechnologies Corp

ADPT

Company Profile

  • Business description

    Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

  • Contact

    1165 Eastlake Avenue East
    SeattleWA98109
    USA

    T: +1 206 659-0067

    https://www.adaptivebiotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2026

    Employees

    624

Stocks News & Analysis

stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.
stocks

Investor Playbook: Can your portfolio handle what’s next?

Testing portfolio resilience in an uncertain market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,165.4039.10-0.42%
CAC 408,400.8931.980.38%
DAX 4026,753.053.100.01%
Dow JONES (US)52,182.65164.90-0.32%
FTSE 10010,950.0547.490.44%
HKSE23,753.84116.240.49%
NASDAQ24,787.57348.70-1.39%
Nikkei 22559,662.021,480.33-2.42%
NZX 50 Index14,303.77130.090.92%
S&P 5007,493.8667.81-0.90%
S&P/ASX 2009,044.7037.50-0.41%
SSE Composite Index3,602.5731.78-0.87%

Market Movers